Item 8.01. Other Events

On June 13, 2022, Alnylam Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the United States Food and Drug Administration has approved the Company's new drug application for AMVUTTRA™ (vutrisiran) an RNAi therapeutic administered via subcutaneous injection once every three months (quarterly) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

The full text of the press release issued in connection with this announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits





99.1      Press Release dated June 13, 2022.

104     Cover Page Interactive Data File (embedded within the Inline XBRL document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses